Related Experiment Video

Updated: May 30, 2026

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors
16:49

Two Methods of Heterokaryon Formation to Discover HCV Restriction Factors

Published on: July 16, 2012

Ceestatin, a novel small molecule inhibitor of hepatitis C virus replication, inhibits

Lee F Peng1, Esperance A K Schaefer, Nicole Maloof

  • 1Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

The Journal of Infectious Diseases
|July 28, 2011
PubMed

Insights

Ceestatin, an anti-Hepatitis C virus (HCV) compound, inhibits 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase, an enzyme crucial for viral replication. This discovery offers a new strategy for developing HCV antiviral therapies.

Area of Science:

  • Virology
  • Biochemistry
  • Drug Discovery

Background:

  • Hepatitis C virus (HCV) infection affects over 170 million people globally, leading to cirrhosis and liver cancer.
  • Developing effective and well-tolerated HCV treatments remains a critical medical need.
  • Ceestatin, a novel small molecule, was previously identified through high-throughput screening for anti-HCV activity.

Purpose of the Study:

  • To identify host or viral protein targets of ceestatin in an unbiased manner.
  • To elucidate the mechanism of action of ceestatin against HCV.
  • To validate 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) synthase as a potential therapeutic target for HCV.

Main Methods:

  • Affinity chromatography coupled with liquid chromatography/mass spectrometry was employed to identify ceestatin's protein targets.
  • Enzyme inhibition assays were performed to assess the effect of ceestatin on HMG-CoA synthase activity.
  • Small interfering RNA (siRNA) was used to knock down HMG-CoA synthase expression and evaluate its impact on HCV replication.

Main Results:

  • Ceestatin was found to bind to and irreversibly inhibit HMG-CoA synthase in a dose-dependent manner.
  • The anti-HCV effects of ceestatin were reversible by HMG-CoA, mevalonic acid, or geranylgeraniol, indicating a link to the mevalonate pathway.
  • Silencing HMG-CoA synthase expression significantly reduced HCV replication, confirming its essential role in the viral life cycle.

Conclusions:

  • Ceestatin exerts its anti-HCV effects by inhibiting HMG-CoA synthase.
  • Ceestatin shows potential as an antiviral agent for HCV, a research tool for studying viral replication, and a cholesterol-lowering drug.
  • The methodology used to discover ceestatin's mechanism can be applied to identify targets for other novel anti-HCV compounds.
Abstract

More Related Videos

A Protocol for Analyzing Hepatitis C Virus Replication13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Inhibitors Of Virion Release01:25

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...
Inhibitors of Virion Maturation and Assembly01:19

Inhibitors of Virion Maturation and Assembly

As part of their replication cycle, certain viruses synthesize long precursor proteins called polyproteins within infected host cells. In human immunodeficiency virus (HIV), two major polyproteins are produced: Gag and Gag-Pol. The Gag polyprotein supplies the structural components of the virus, while Gag-Pol includes essential viral enzymes such as reverse transcriptase, integrase, and protease. After synthesis, these polyproteins move to the host cell membrane, where they assemble into an...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...